Serum Visfatin Level in Gestational Diabetes Mellitus

ackground: Visfatin is a newly discovered adipocytokine. There is conflicting data regarding visfatin in gestational diabetes mellitus (GDM). Aim: The purpose of the present study was to investigate the possible alterations of serum levels of visfatin in patients with GDM. Subjects and Methods: 50 pregnant women were enrolled in the study, were divided into two groups; group I included 30 pregnant women with GDM and group II included 20 age and body mass index-matched pregnant women with normal glucose tolerance (NGT). Anthropometric and laboratory measurements including serum visfatin levels were assessed, and values were analyzed to compare the differences among the groups. Results: Regarding fasting visfatin level, GDM group had higher levels in comparison to NGT group (24.73±25.40 ng/ml vs 7.85±2.83 ng/ml in group I and group II respectively, p<0.01), also GDM group had higher 1 hr postprandial visfatin levels than that of NGT group (40.53±25.40 ng/ml vs 16.90±3.02 ng/ml in group I and group II Respectively, p<0.01).There was a significant positive correlation between fasting visfatin and BMI (r=0.50, p<0.01), HbA1C(r=0.655, p<0.01), fasting serum insulin (r=0.386, p<0.05) and HOMA-IR (r=0.554, p<0.01). And, there was a significant positive correlation between 1hour post-prandial visfatin and BMI (r=0.44, p<0.01), HbA1C(r=0.609, p<0.01), fasting serum insulin (r=0.397, p<0.01) and HOMA-IR(r=0.575, p